The burden of adult asthma in Finland: impact of disease severity and eosinophil count on health care resource utilization

References

• Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, Adcock IM, Bateman ED, Bel EH, Bleecker ER, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43:343–373. doi:10.1183/09031936.00202013.
   PubMed Web of Science ®Google Scholar
• Wenzel S. Severe asthma: from characteristics to phenotypes to endotypes. Clin Exp Allergy 2012;42:650–658. doi:10.1111/j.1365-2222.2011.03929.x.
   PubMed Web of Science ®Google Scholar
• G. B. D. Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med. 2017;5:691–706. doi:10.1016/S2213-2600(17)30293-X.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Asthma. Key facts 2017. http://www.who.int/news-room/fact-sheets/detail/asthma. Accessed Sep, 2018.
   Google Scholar
• Jousilahti P, Haahtela T, Laatikainen T, Makela M, Vartiainen E. Asthma and respiratory allergy prevalence is still increasing among Finnish young adults. Eur Respir J. 2016;47:985–987. doi:10.1183/13993003.01702-2015.
   PubMed Web of Science ®Google Scholar
• Pavord ID. Eosinophilic phenotypes of airway disease. Ann Am Thorac Soc. 2013;10: S143–S149. doi:10.1513/AnnalsATS.201306-168AW.
   PubMedGoogle Scholar
• Walsh CJ, Zaihra T, Benedetti A, Fugere C, Olivenstein R, Lemiere C, Hamid Q, Martin JG. Exacerbation risk in severe asthma is stratified by inflammatory phenotype using longitudinal measures of sputum eosinophils. Clin Exp Allergy 2016;46:1291–1302. doi:10.1111/cea.12762.
   PubMed Web of Science ®Google Scholar
• Demarche SF, Schleich FN, Paulus VA, Henket MA, Van Hees TJ, Louis RE. Asthma control and sputum eosinophils: a longitudinal study in daily practice. J Allergy Clin Immunol Pract. 2017;5:1335–1343.e5. doi:10.1016/j.jaip.2017.01.026.
   PubMed Web of Science ®Google Scholar
• Ilmarinen P, Tuomisto LE, Niemela O, Kankaanranta H. Prevalence of patients eligible for anti-IL-5 treatment in a cohort of adult-onset asthma. J Allergy Clin Immunol Pract. 2019;7:165–174.e4. doi:10.1016/j.jaip.2018.05.032.
   PubMed Web of Science ®Google Scholar
• Hekking PP, Wener RR, Amelink M, Zwinderman AH, Bouvy ML, Bel EH. The prevalence of severe refractory asthma. J Allergy Clin Immunol. 2015;135:896–902. doi:10.1016/j.jaci.2014.08.042.
   PubMed Web of Science ®Google Scholar
• Larsson K, Stallberg B, Lisspers K, Telg G, Johansson G, Thuresson M, Janson C. Prevalence and management of severe asthma in primary care: an observational cohort study in Sweden (PACEHR). Respir Res. 2018;19:12. doi:10.1186/s12931-018-0719-x.
   PubMed Web of Science ®Google Scholar
• Varsano S, Segev D, Shitrit D. Severe and non-severe asthma in the community: A large electronic database analysis. Respir Med. 2017;123:131–139. doi:10.1016/j.rmed.2016.12.017.
   PubMed Web of Science ®Google Scholar
• Chen S, Golam S, Myers J, Bly C, Smolen H, Xu X. Systematic literature review of the clinical, humanistic, and economic burden associated with asthma uncontrolled by GINA Steps 4 or 5 treatment. Curr Med Res Opin. 2018;34:1–14. doi:10.1080/03007995.2018.1505352.
   PubMed Web of Science ®Google Scholar
• Nunes C, Pereira AM, Morais-Almeida M. Asthma costs and social impact. Asthma Res Pract. 2017;3:1.doi:10.1186/s40733-016-0029-3.
   PubMedGoogle Scholar
• Janson C, Lisspers K, Stallberg B, Johansson G, Telg G, Thuresson M, Nordahl Christensen H, Larsson K. Health care resource utilization and cost for asthma patients regularly treated with oral corticosteroids - a Swedish observational cohort study (PACEHR). Respir Res. 2018;19:168. doi:10.1186/s12931-018-0855-3.
   PubMed Web of Science ®Google Scholar
• Mäkelä MJ, Christensen HN, Karlsson A, Rastogi S, Kettunen K. Health care resource utilization and characteristics of patients with eosinophilic asthma in secondary health care in Finland. Eu Clin Respir J 2018;5:1458560. doi:10.1080/20018525.2018.1458560.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–383. doi:10.1016/0021-9681(87)90171-8.
   PubMedGoogle Scholar
• Thygesen SK, Christiansen CF, Christensen S, Lash TL, Sørensen HT. The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of Patients. BMC Med Res Methodol. 2011;11:83. doi:10.1186/1471-2288-11-83.
   PubMed Web of Science ®Google Scholar
• Kerkhof M, Tran TN, Soriano JB, Golam S, Gibson D, Hillyer EV, Price DB. Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population. Thorax 2018;73:116–124. doi:10.1136/thoraxjnl-2017-210531.
   PubMed Web of Science ®Google Scholar
• Price D, Wilson AM, Chisholm A, Rigazio A, Burden A, Thomas M, King C. Predicting frequent asthma exacerbations using blood eosinophil count and other patient data routinely available in clinical practice. J Asthma Allergy 2016;9:1–12. doi:10.2147/JAA.S97973.
   PubMed Web of Science ®Google Scholar
• Zeiger RS, Schatz M, Li Q, Chen W, Khatry DB, Gossage D, Tran TN. High blood eosinophil count is a risk factor for future asthma exacerbations in adult persistent asthma. J Allergy Clin Immunol Pract. 2014;2:741–750. doi:10.1016/j.jaip.2014.06.005.
   PubMed Web of Science ®Google Scholar
• Chupp GL, Bradford ES, Albers FC, Bratton DJ, Wang-Jairaj J, Nelsen LM, Trevor JL, Magnan A, ten Brinke A. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med. 2017;5:390–400. doi:10.1016/S2213-2600(17)30125-X.
   PubMed Web of Science ®Google Scholar
• Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, Ortega HG, Pavord ID. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 2014;371:1189–1197. doi:10.1056/NEJMoa1403291.
   PubMed Web of Science ®Google Scholar
• Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, Ortega H, Chanez P. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012;380:651–659. doi:10.1016/S0140-6736(12)60988-X.
   PubMed Web of Science ®Google Scholar
• Buhl R, Humbert M, Bjermer L, Chanez P, Heaney LG, Pavord I, Quirce S, Virchow JC, Holgate S. Severe eosinophilic asthma: a roadmap to consensus. Eur Respir J. 2017;49:1700634. doi:10.1183/13993003.00634-2017.
   PubMed Web of Science ®Google Scholar
• Chastek B, Korrer S, Nagar SP, Albers F, Yancey S, Ortega H, Forshag M, Dalal AA. Economic burden of illness among patients with severe asthma in a managed care setting. J Manage Care Spec Pharm. 2016;22:848–861. doi:10.18553/jmcp.2016.22.7.848.
   PubMedGoogle Scholar
• Antonicelli L, Bucca C, Neri M, De Benedetto F, Sabbatani P, Bonifazi F, Eichler HG, Zhang Q, Yin DD. Asthma severity and medical resource utilisation. Eur Respir J. 2004;23:723–729. doi:10.1183/09031936.04.00004904.
   PubMed Web of Science ®Google Scholar
• Haahtela T, Herse F, Karjalainen J, Klaukka T, Linna M, Leskelä R-L, Selroos O, Reissell E. The Finnish experience to save asthma costs by improving care in 1987-2013. J Allergy Clin Immunol. 2017;139:408–414. e402. doi:10.1016/j.jaci.2016.12.001.
   PubMed Web of Science ®Google Scholar
• Bahadori K, Doyle-Waters MM, Marra C, Lynd L, Alasaly K, Swiston J, FitzGerald JM. Economic burden of asthma: a systematic review. BMC Pulm Med. 2009;9:24.doi:10.1186/1471-2466-9-24.
   PubMedGoogle Scholar